Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
Sophia T. Pallenberg, Marie‐Madlen Pust, Ilona Rosenboom, Gesine Hansen, Lutz Wiehlmann, Anna‐Maria Dittrich, Burkhard Tümmler
Abstract
Shotgun metagenome sequencing of respiratory secretions with spike-in controls for normalization demonstrated that 1 year of high-efficient CFTR modulation with elexacaftor/tezacaftor/ivacaftor extensively reduced the bacterial load. Longer observation periods will be necessary to resolve whether the partial reversion of the basic defect that is achieved with ELX/TEZ/IVA is sufficient in the long run to render the CF lungs robust against the recolonization with common opportunistic pathogens.
Topics & Concepts
IvacaftorCystic fibrosisMetagenomicsAirwayMedicineComputational biologyBiologyInternal medicineGeneticsCystic fibrosis transmembrane conductance regulatorGeneSurgeryCystic Fibrosis Research Advances